NEW YORK, April 2, 2013 /PRNewswire/ -- OTC
Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced that DiagnoCure
Inc. (OTCQX: DGCRF; TSX: CUR), a life sciences company that
develops and commercializes high-value cancer diagnostic tests, has
chosen to trade on OTCQX®, the best OTC marketplace with qualified
companies.
(Logo: http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
)
DiagnoCure will begin trading today on OTCQX International, a
segment of the OTCQX marketplace reserved for high-quality non-U.S.
companies listed on a qualified stock exchange in their home
country. Investors can find current financial disclosure and
Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"We are pleased DiagnoCure has chosen to trade on OTCQX," said
R. Cromwell Coulson, President and
CEO of OTC Markets Group. "OTCQX is the highest OTC
marketplace offering qualifying companies the means to grow their
U.S. shareholder base through high-quality disclosure, transparent
trading and ease of access to company information."
"We are proud to join OTCQX, which will enable us to provide our
U.S. investors with timely news and information to help them better
analyze, value and trade our securities," said Chantal Miklosi, Chief Financial Officer of
DiagnoCure.
Dorsey & Whitney LLP will serve as DiagnoCure's Principal
American Liaison ("PAL") on OTCQX, responsible for providing
professional guidance on OTCQX requirements and U.S. securities
laws.
DiagnoCure is a life sciences corporation that develops and
commercializes high-value cancer diagnostic tests that increase
clinician and patient confidence in making critical treatment
decisions. In 2008, the corporation launched a colorectal
cancer staging test through its U.S. CLIA laboratory.
Previstage™ GCC is currently available for
licensing. The company has granted a worldwide exclusive
license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc.
operating as Hologic Gen-Probe, for the development and
commercialization of prostate cancer test using PCA3, DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States.
DiagnoCure trades in the U.S. on OTCQX under the symbol
"DGCRF."
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and
Connected financial marketplaces for 10,000 U.S. and global
securities. Through our OTC Link® ATS, we directly link a diverse
network of broker-dealers that provide liquidity and execution
services for a wide spectrum of securities. We organize these
securities into marketplaces to better inform investors of
opportunities and risks – OTCQX®, The Best Marketplace with
Qualified Companies; OTCQB®, The Venture Stage Marketplace with
U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with
Variable Reporting Companies. Our data-driven platform enables
investors to easily trade through the broker of their choice at the
best possible price and empowers a broad range of companies to
improve the quality and availability of information for their
investors. To learn more about how we create better informed and
more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTCQX RSS Feed
SOURCE OTC Markets Group Inc.